About OKYO Pharma
OKYO Pharma ADR (NASDAQ:OKYO) is a biopharmaceutical company focused on developing innovative treatments to combat eye diseases, particularly those causing significant discomfort and vision impairment. Its pipeline of projects revolves around novel therapeutic peptides and small molecules aimed at addressing unmet needs in ophthalmology, with a keen emphasis on dry eye disease and chronic pain in ocular surfaces. OKYO Pharma's objective is to advance these cutting-edge therapies from the research stage through clinical trials, with the aim of eventually bringing new solutions to patients suffering from these debilitating conditions. The company is dedicated to improving quality of life through scientific breakthroughs and rigorous testing of their potential medications.
Snapshot
Operations
Produtos e/ou serviços de OKYO Pharma
- Development of novel therapeutics for ocular diseases focusing on dry eye disease.
- Advancement of a proprietary GPCR agonist for treating ocular pain and inflammation.
- Researching non-opioid, receptor-targeted therapeutics for chronic pain management.
- Exploration of innovative treatments for age-related macular degeneration (AMD).
- Investigation into novel drug delivery systems for enhanced ocular drug bioavailability.
- Collaboration on biomedical research projects to identify potential new drug candidates for various diseases.
equipe executiva do OKYO Pharma
- Dr. Gary S. Jacob Ph.D.Chief Development Officer & Director
- Mr. Robert J. Dempsey M.B.A.CEO & Executive Director
- Mr. Michael Paul BeckFounder
- Ms. Keeren ShahChief Financial Officer
- Dr. Rajkumar Patil Ph.D.Chief Scientific Officer